ZIOPHARM Oncology (NASDAQ:ZIOP) Stock Price Down 6.6%

Shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) traded down 6.6% during mid-day trading on Monday . The company traded as low as $5.94 and last traded at $6.06, 2,187,048 shares changed hands during mid-day trading. An increase of 23% from the average session volume of 1,782,588 shares. The stock had previously closed at $6.49.

A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of ZIOPHARM Oncology from a “buy” rating to a “hold” rating in a report on Saturday, May 18th. HC Wainwright reissued a “buy” rating and issued a $5.50 price target on shares of ZIOPHARM Oncology in a report on Thursday, May 9th. Finally, BidaskClub raised shares of ZIOPHARM Oncology from a “buy” rating to a “strong-buy” rating in a report on Monday, June 17th. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $5.75.

The company has a market capitalization of $1.05 billion, a PE ratio of -12.63 and a beta of 2.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.89 and a quick ratio of 8.89. The stock’s fifty day moving average price is $5.89.

ZIOPHARM Oncology (NASDAQ:ZIOP) last released its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.09) by $0.01. On average, equities research analysts predict that ZIOPHARM Oncology Inc. will post -0.33 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in ZIOP. SG Americas Securities LLC raised its holdings in ZIOPHARM Oncology by 1,086.8% in the 2nd quarter. SG Americas Securities LLC now owns 378,669 shares of the biotechnology company’s stock valued at $2,208,000 after acquiring an additional 346,763 shares during the period. D. E. Shaw & Co. Inc. raised its holdings in ZIOPHARM Oncology by 39.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 530,108 shares of the biotechnology company’s stock valued at $991,000 after acquiring an additional 150,760 shares during the period. Geode Capital Management LLC raised its holdings in ZIOPHARM Oncology by 10.3% in the 4th quarter. Geode Capital Management LLC now owns 1,552,016 shares of the biotechnology company’s stock valued at $2,902,000 after acquiring an additional 145,129 shares during the period. Two Sigma Investments LP bought a new position in ZIOPHARM Oncology in the 4th quarter valued at about $212,000. Finally, Iridian Asset Management LLC CT bought a new position in ZIOPHARM Oncology in the 1st quarter valued at about $369,000. 38.95% of the stock is currently owned by hedge funds and other institutional investors.

ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Sleeping Beauty (SB), which is based on the genetic engineering of immune cells using a non-viral transposon/transposase system to reprogram T-cells outside of the body for infusion; and Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to attack cancer cells.

Recommended Story: What is net income?

Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.